Last reviewed · How we verify

NCT05269888: CoVaR-MS

Covid-19 Vaccine Immune Response in Multiple Sclerosis

Active, enrolled Last updated 4 February 2025
What this trial tests

trial testing Blood Test 1 in Multiple Sclerosis in 240 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
16 February 2022
Primary endpoint
30 December 2024
30 December 2025

Quick facts

Lead sponsorUniversity Hospitals of North Midlands NHS Trust
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment240
Start date16 February 2022
Primary completion30 December 2024
Estimated completion30 December 2025
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University Hospitals of North Midlands NHS Trust

Who can join

18 and older, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Coronavirus (Covid-19) has affected millions of people worldwide. Vaccines to prevent Covid-19 infection have been offered to reduce the risk of infection. While these vaccines have been offered to people with multiple sclerosis (MS), they have not been tested in these individuals. It is uncertain whether people with MS will develop protective antibodies after a Covid-19 vaccination and how long these antibodies will last. The investigators are planning to study the immune response to the full course of Covid-19 vaccine in people with MS (study group) and compare this to people without MS or immune suppression (control group).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

Other University Hospitals of North Midlands NHS Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05269888.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing